A study of mechanisms underlying amitriptyline-induced acute lung function impairment

Area of Science:

• Pharmacology
• Pulmonary Medicine
• Toxicology

Background:

• Tricyclic antidepressants (TCAs) like amitriptyline can cause adverse effects.
• Amitriptyline's impact on lung function, particularly vasoconstriction and bronchoconstriction, shares similarities with acute lung injury (ALI) and adult respiratory distress syndrome (ARDS).

Purpose of the Study:

• To investigate the mechanisms behind amitriptyline-induced vasoconstriction and bronchoconstriction in isolated rat lungs.
• To explore potential therapeutic targets for mitigating amitriptyline-induced lung dysfunction.

Main Methods:

• Isolated rat lungs were exposed to varying concentrations of amitriptyline (50 and 100 microM).
• Lungs were pre-treated with various agents including anti-inflammatory drugs, antioxidants, enzyme inhibitors (arachidonic acid cascade), and receptor antagonists.
• Measurements included perfusion flow (vasoconstriction) and airway conductance (bronchoconstriction).

Main Results:

• Amitriptyline caused a dose-dependent and rapid decrease in lung perfusion flow and airway conductance.
• Vasoconstriction was significantly reduced by staurosporine (protein kinase inhibitor), S-nitrosoglutathione (NO-donor), and PD 145065 (endothelin receptor antagonist).
• Bronchoconstriction was attenuated by salbutamol (beta(2)-agonist), WEB2086 (platelet-activating factor antagonist), staurosporine, and PD 145065.

Conclusions:

• Protein kinase activation, endothelin signaling, and platelet-activating factor (PAF) play crucial roles in amitriptyline-induced lung vasoconstriction and bronchoconstriction.
• These findings suggest potential therapeutic strategies for managing amitriptyline-related lung injury.
• The study highlights the relevance of these pathways in experimental models of acute lung injury.